New Hope Corporation Ltd (ASX: NHC) shares have delivered investors some seriously outsized returns over the past year.

How seriously?

Well, in late morning trade on Monday, shares in the S&P/ASX 200 Index (ASX: XJO) coal stock are trading for $5.68 apiece. This sees the share price up 41.7% since this time last year, smashing the 2% 12-month losses posted by the ASX 200.

And that’s not including the two fully-franked New Hope dividends, totalling 40 cents per share, that the coal miner paid out (or shortly will pay out) over this period. If we add those back in, then the accumulated value of New Hope shares has surged 51.6% in a year.

New Hope stock traded ex-dividend on 21 September. If you held shares at market close on 21 September, you can expect the final fully-franked 30-cent-per-share dividend to land in your bank account on 15 October.

At current prices, New Hope stock trades on a fully-franked trailing dividend yield of 7%. That equates to a grossed-up yield of 10.1%, once we account for those franking credits.

Atop its own operational successes on and below the ground, New Hope has been benefiting from resurgent global coal prices.

At US$144 per tonne, thermal coal (primarily used for energy production) prices are up approximately 35% in 12 months. And thermal coal prices have lifted more than 21% since the end of February, amid the worldwide energy crunch following the outbreak of the Iran war.

But following on this strong run, is the ASX 200 coal stock now a buy, hold, or sell?

New Hope shares: Buy, hold, or sell?

Fairmont Equities’ Michael Gable recently ran his slide rule over the ASX 200 coal miner (courtesy of The Bull).

“I remain bullish about this thermal coal producer, as the war in Iran is leading other countries to lift demand for thermal coal to offset instability in gas markets,” Gable noted.

Commenting on the miner’s recent performance and passive income appeal, Gable said:

The company generated saleable coal production of 11.5 million tonnes in full year 2026, up 7.6 per cent on the prior corresponding period. Production was above market expectations as was the final, fully franked dividend of 30 cents a share.

Along with lifting production, New Hope also increased its total coal resources over the year, which grew to 2.96 billion tonnes as at 31 May, up from 2.55 billion tonnes year on year.

Summarising his hold recommendation on New Hope shares, Gable concluded, “The share price uptrend since early July is sustainable, in my view.”

The post Up 42% and paying a 7% dividend yield, should I buy New Hope shares today? appeared first on The Motley Fool Australia.

More reading

• Why I’d invest $50,000 of superannuation in New Hope, Mineral Resources and BHP shares
• Soul Patts vs Macquarie Group: Best ASX dividend stock for retirees?
• Which ASX shares just got downgraded by brokers?
• Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares
• Whitehaven Coal vs New Hope: Which ASX coal share offers better value today?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Dateline Resources Ltd (ASX: DTR) share price is flying on Monday morning.

The gold explorer’s shares are currently up 46.03% to 9.2 cents, after finishing Friday’s session at just 6.3 cents.

It’s a welcome change for shareholders, with the stock having lost almost 60% of its value in 2026, and more than 80% over the past year.

Much of that decline has come amid legal troubles surrounding its flagship US gold project.

But today’s announcement has given investors another reason to get excited.

So, let’s take a closer look at see what happened.

Why are Dateline shares rocketing 46%?

In its latest announcement, Dateline revealed that the US Government has stepped in to support the company in its ongoing legal battle.

The US Department of Justice (DOJ) has filed a motion asking the court to lift the injunction preventing work at its Colosseum project in California.

The restriction has been in place since 10 August, following legal action brought by environmental group National Parks Conservation Association (NPCA).

The group is challenging the project’s approved plan of operations, leaving Dateline unable to continue work at the site.

But the US Government wants the company to be able to get back to work while the appeal continues.

In its filing, the DOJ argues that the court got its original decision wrong and that the injunction is harming US national security interests.

And the project’s rare earth potential is also playing a part.

Michael Cadenazzi, Assistant Secretary of War for Industrial Base Policy, has provided a sworn declaration highlighting Colosseum’s potential to produce rare earth elements.

These minerals are considered critical to US national security, especially as the country looks to reduce its reliance on China.

The Asian superpower currently controls around 90% of the world’s rare earth processing.

What’s next for Dateline shares?

The next big date to watch is 26 October, when the court is scheduled to hear the applications to suspend the injunction.

Both Dateline and the US Government have filed separate motions, although the NPCA has already indicated it will oppose them.

If the applications are successful, Dateline could resume work at Colosseum while the appeal continues.

The company’s feasibility study outlined a 10.4 year mine life, with approximately 573,000 ounces of gold production.

The study also forecasts US$1.08 billion in undiscounted pre-tax free cash flow, based on a gold price of US $4,200 per ounce.

However, I’ll be watching the next month’s hearing very closely before getting too excited about today’s massive share price rally.

The post Guess which ASX stock is rocketing 46% today appeared first on The Motley Fool Australia.

More reading

• 3 cheap ASX shares I would buy now
• Up 42% and paying a 7% dividend yield, should I buy New Hope shares today?
• 6 ASX shares set to soar 39% to 135%
• If I buy $6,000 of Fortescue shares, how much dividend income will I receive?
• Steadfast vs AUB: Which insurance broker offers better value?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are up 0.3% to 8,692.5 points on Monday.

The market fell to a 15-week low last week as bond yields soared and expectations of an interest rate rise increased.

The Reserve Bank of Australia will announce its next cash rate decision tomorrow at 2:30pm.

Meanwhile, if you’re looking for buy-the-dip inspiration, experts say these ASX stocks have big potential upside.

Zip Co Ltd (ASX: ZIP)

The Zip share price is $2, up 0.76% on Monday.

Over the past month, this ASX 200 financial share has fallen 21%.

UBS renewed its buy rating on Zip shares with a 12-month price target of $4.70.

This suggests a potential 135% upside ahead.

Mesoblast Ltd (ASX: MSB)

The Mesoblast share price is $2.08, down 3.7% today.

Over the past month, this ASX healthcare share has fallen 16%.

Bell Potter has a buy recommendation on Mesoblast shares with a $4.45 target.

This implies the Mesoblast share price could double over the next 12 months.

Analyst John Hester issued an updated note following news of the T-Cell Proliferation Inhibition Assay (TIBA).

He said:

Mesoblast has announced FDA approval of an additional potency assay for Ryoncil.

MSB had not previously disclosed the development of this assay, however, it collaborated with the FDA on the project.

The assay will be equally applicable to the manufacture of rexlemestrocel-L.

MSB has extensive IP around both Ryoncil and Rexlemestrocel-L (aka Revascor).

Ryoncil carries Orphan Drug Designation and long life patents.

The development of the new TIBA assay further extends the moat around future revenues.

Xero Ltd (ASX: XRO)

The Xero share price is $57.79, up 0.75% today. 

Over the past month, this ASX 200 tech share has fallen 33%.

UBS renewed its buy rating on Xero shares with a $127 target.

This suggests a potential 120% upside ahead.

WiseTech Global Ltd (ASX: WTC)

The WiseTech share price is $31.91, up 1.85% today.

Over the past month, this ASX 200 tech share has fallen 21%.

UBS has a buy rating with a $56 target on WiseTech shares.

This suggests a potential 75% upside ahead.

Ramelius Resources Ltd (ASX: RMS)

The Ramelius Resources share price is $3.82, down 1.29% today.

Over the past month, this ASX 200 gold mining share has edged 4% lower.

Canaccord Genuity upgraded Ramelius Resources shares to a buy call with a $6.15 target.

This indicates potential capital gains of 61% over the next year. 

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is $161.81, up 0.5% today. 

This ASX 200 healthcare share has fallen 11% over the past month.

Citi renewed its buy rating on Pro Medicus shares with a $225 target.

This implies potential capital growth of 39% over the next year.

The post 6 ASX shares set to soar 39% to 135% appeared first on The Motley Fool Australia.

More reading

• How much could the Xero share price rise in the next year?
• Buy, hold, sell: Xero, South32, Woodside shares
• Could Mesoblast shares rise over 100% in 12 months?
• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has positions in Zip Co. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.